191 related articles for article (PubMed ID: 23817384)
1. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.
Gentry BG; Vollmer LE; Hall ED; Borysko KZ; Zemlicka J; Kamil JP; Drach JC
Antimicrob Agents Chemother; 2013 Sep; 57(9):4343-8. PubMed ID: 23817384
[TBL] [Abstract][Full Text] [Related]
2. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
James SH; Hartline CB; Harden EA; Driebe EM; Schupp JM; Engelthaler DM; Keim PS; Bowlin TL; Kern ER; Prichard MN
Antimicrob Agents Chemother; 2011 Oct; 55(10):4682-91. PubMed ID: 21788463
[TBL] [Abstract][Full Text] [Related]
3. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.
Gentry BG; Drach JC
Antimicrob Agents Chemother; 2014; 58(4):2329-33. PubMed ID: 24514084
[TBL] [Abstract][Full Text] [Related]
5. Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.
Gentry BG; Phan Q; Hall ED; Breitenbach JM; Borysko KZ; Kamil JP; Townsend LB; Drach JC
Antimicrob Agents Chemother; 2015 Jan; 59(1):226-32. PubMed ID: 25348532
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
7. Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.
Chen H; Li C; Zemlicka J; Gentry BG; Bowlin TL; Coen DM
Antimicrob Agents Chemother; 2016 Jul; 60(7):4176-82. PubMed ID: 27139481
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir.
Gentry BG; Kamil JP; Coen DM; Zemlicka J; Drach JC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3093-8. PubMed ID: 20547817
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
Chou S; Bowlin TL
Antimicrob Agents Chemother; 2011 Jan; 55(1):382-4. PubMed ID: 21041510
[TBL] [Abstract][Full Text] [Related]
10. Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants.
Baldanti F; Sarasini A; Drach JC; Zemlicka J; Gerna G
Antiviral Res; 2002 Dec; 56(3):273-8. PubMed ID: 12406510
[TBL] [Abstract][Full Text] [Related]
11. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.
Chou S; Komazin-Meredith G; Williams JD; Bowlin TL
Antimicrob Agents Chemother; 2014; 58(3):1809-12. PubMed ID: 24379208
[TBL] [Abstract][Full Text] [Related]
13. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Tenney DJ; Yamanaka G; Voss SM; Cianci CW; Tuomari AV; Sheaffer AK; Alam M; Colonno RJ
Antimicrob Agents Chemother; 1997 Dec; 41(12):2680-5. PubMed ID: 9420038
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
Chou S; Ercolani RJ; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
[TBL] [Abstract][Full Text] [Related]
15. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
16. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Cytomegaloviruses with Different Ganciclovir Sensitivities from UL97 Mutation Retain Their Replication Efficiency and Some Kinase Activity
Wong DD; van Zuylen WJ; Hamilton ST; Steingruber M; Sonntag E; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262766
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Bigley TM; Reitsma JM; Terhune SS
J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
[TBL] [Abstract][Full Text] [Related]
19. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E.
Ijichi O; Michel D; Mertens T; Miyata K; Eizuru Y
Antiviral Res; 2002 Feb; 53(2):135-42. PubMed ID: 11750939
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system.
Baldanti F; Michel D; Simoncini L; Heuschmid M; Zimmermann A; Minisini R; Schaarschmidt P; Schmid T; Gerna G; Mertens T
Antiviral Res; 2002 Apr; 54(1):59-67. PubMed ID: 11888658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
